By The number of active prescriptions for the opioid disorder treatment drug buprenorphine remained constant during the first year of the COVID-19 pandemic, but the number of new prescriptions for the treatment was far below what would normally have been expected, according to a new RAND Corporation study.
Buprenorphine use remained stable during first year of pandemic
Close Up Scientist using microscope in laboratory room while making medical testing and research
Comments